Results from a Bayesian network meta-analysis further supported its superiority: cadonilimab plus chemotherapy offered the greatest OS and PFS benefits among various ICI-based regimens, including nivolumab, pembrolizumab, sintilimab, tislelizumab, and sugemalimab, for HER2-negative GC/GEJC patients with positive PD-L1 CPS (36). The gene discussed is ERBB2; the disease is gastric cancer.